期刊文献+

洛汀新与凯时联合治疗糖尿病肾病35例疗效观察 被引量:1

Curative Observation on Treatment of Diabetic Nephropathy with Lotensin and Lipo PGE1
下载PDF
导出
摘要 目的观察洛汀新、凯时治疗糖尿病肾病的临床疗效。方法治疗组35例在糖尿病饮食、胰岛素常规治疗的同时应用洛汀新10-20 mg/d,凯时10 mg静推,1次/d,2周为1疗程,可重复1-2个疗程,并与常规治疗对照。结果治疗组35例,显效26例,有效5例,无效4例,而对照组32例,显效10例,有效8例,无效14例。在减少蛋白尿方面与对照组进行比较,结果明显优于对照组(P〈0.05)。结论加用洛汀新、凯时治疗糖尿病肾病毒副作用少,并有很好的治疗效果。 Objective To observe the curative effect on treatment of diabetic nephropathy with lotensin and lipo PGE1. Methods 35 cases of such patient were treated with lotensin 10 - 20 mg and kaishi 10mg per day (twice week as a course) and results were compared with control group. Results The excellent effect was in 26 cases, good effect in 5 cases and no effect in 4 in therapy group and excellent effect was in 10 cases, good effect in 8 cases and no effect in 14 in control group. There was significant difference in urine protein in both groups with P 〈 0.05. Conclusion The combination use of lotensin and lipo PGE1 and insulin might have less side effect and can ensure curative effect.
作者 王向明
机构地区 大庆市第四医院
出处 《黑龙江医学》 2008年第5期350-351,共2页 Heilongjiang Medical Journal
关键词 洛汀新 凯时 糖尿病肾病 Lotensin Lipo PGE1 Diabetic nephropathy
  • 相关文献

参考文献5

二级参考文献25

  • 1于德民,吴锐,尹潍,袁咏.实验性链脲佐菌素糖尿病动物模型的研究[J].中国糖尿病杂志,1995,3(2):105-109. 被引量:425
  • 2[2]Brady HR, Nathaniel D, Laurac, et al. Monocyte chemoattractant Protein-1 levels in patients with glomerular disease. Am J kidney Dis ,1996,27:640-646.
  • 3[3]Brady HR, Rumancik M, Tan L, et al. Glomerular expression of MCP-1 in Experimental and human GN. Lab Invest ,1994,71:536-542.
  • 4[4]Wada T, Yokoyama H, Su SB, et al. Monitoring urinary levels of monocyte chemotactic and activating factor reflects disease activity of lupus nephritis. Kidney Int,1996,49:761-767.
  • 5[1]Rossing P, Hommel E, Smidt UM, et al. Reduction in albuminuriu pre dicts diminished progression in diabetic nepbropathy. Kidney Int, 1994,45 (suppl): 145-149.
  • 6[2]Ruseo D, Pisani A, Balletta MM, et al, Additive antiproteinuric effect of converting enzyme inhibitor and Losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis, 1999, 33 (5): 851-856.
  • 7[3]Kunzelman CL, Nelson RG, Knowler WC, et al. Proteinuria determines prognosis in type 2 (non-insulin-dependent) diabetes. Kidney Int, 1988, 33 (1): 197.
  • 8[4]Mogensen CE, Schmitz A, Christensen CK. Comparative renal pathophvsiology relevant to IDDM and NIDDM patients. Diabetes Metab Rev, 1988, 4 (5): 453-483.
  • 9[5]Klahr S, Morrissey J. Angiotensin Ⅱ and-ene expression in the kidney. Am J Kidney Dis, 1998, 31 (1): 171-176.
  • 10[6]Liu BC, Chen Q, Luo DD, et al. Mechanisms of irbesartan in prevention of renal lesion in streptozotocin-induced diabetic rats. Acta Phar macol Sin, 2003, 24 (1): 67-73.

共引文献194

同被引文献4

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部